Repligen
Repligen Corporation, a leading player in the bioprocessing industry, is headquartered in the United States. Founded in 1981, the company has established itself as a key provider of innovative solutions for the development and manufacture of biologics. With a strong presence in major operational regions including Europe and Asia, Repligen focuses on areas such as protein purification, cell culture, and bioprocessing technologies. The company’s core products, including its unique chromatography resins and single-use systems, are designed to enhance efficiency and productivity in biomanufacturing. Repligen's commitment to quality and innovation has positioned it as a trusted partner for biopharmaceutical companies worldwide. Notable achievements include significant growth through strategic acquisitions, solidifying its market position as a frontrunner in bioprocessing solutions.
DitchCarbon Score
How does Repligen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Repligen's score of 54 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Repligen's reported carbon emissions
In 2024, Repligen reported total carbon emissions of approximately 22,057,000 kg CO2e, with Scope 1 emissions accounting for about 1,728,000 kg CO2e. Notably, there were no reported Scope 2 emissions for this year. In comparison, the previous year, 2023, saw total emissions of about 18,099,000 kg CO2e, with Scope 1 emissions at approximately 2,236,000 kg CO2e and Scope 2 emissions at about 959,000 kg CO2e. Repligen has set ambitious climate commitments, aiming to reduce Scope 1 emissions to near zero by 2025 and to achieve a 30% reduction in Scope 1 and Scope 2 emissions from a 2022 baseline by 2030. Additionally, they have successfully met a near-term objective of reducing global site carbon emissions by 10% from 2020 to 2022, while also expanding renewable energy participation across their sites. The company is committed to achieving net-zero emissions by 2050, as validated by the Science Based Targets initiative (SBTi). This long-term goal aligns with their ongoing efforts to enhance sustainability within the pharmaceutical and biotechnology sectors.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 517,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,219,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | - |
| Scope 3 | - | - | - | 00,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Repligen is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
